RALEIGH, N.C.–(BUSINESS WIRE)–Merz North America announced today that Merz aesthetics products
including Xeomin^®, Cellfina^®, Radiesse^®,
Ultherapy^® and DeScribe^® PFD Patch will be
featured in oral and online ePoster presentations at the American
Academy of Dermatology (AAD) annual meeting in San Diego, CA, taking
place February 16-20, 2018.

“Each year, AAD provides Merz with the opportunity to connect with
leaders in dermatology. This year, we are pleased to support research
about our products and share valuable data from trailblazing clinicians
as we advance the science of medical aesthetics,” said Terri Phillips,
Vice President and Head of Global Medical Affairs. “In line with our
vision to become the most admired, trusted and innovative aesthetics
company, we work tirelessly to build strong and lasting relationships
with dermatologists to help people live better, feel better and look
better.”

Oral Presentation

Radiesse^®

• Dissolving calcium hydroxylapatite filler using sodium thiosulfate: a
  proof-of-concept clinical study. Deanne Mraz Robinson, MD –
  Connecticut Dermatology Group; Norwalk, Connecticut. [#7598, Friday,
  February 16, 2018: 9:15 – 9:20 am, ePoster Presentation Center 2 in
  Exhibit Hall]*

Poster Presentations
ePoster presentations will be available
for viewing on the monitors in the Exhibit Hall from Friday, February 16
to Monday, February 19.

Multiple Merz Products

• Combined treatment of striae using calcium hydroxylapatite, ascorbic
  acid delivered by microneedling, and microfocused ultrasound. Gabriela
  Casabona, MD – Clínica Vida; São Paulo, Brazil. [#7574]*
• Improving skin laxity and the appearance of lines in the neck and
  décolletage using combined treatment with microfocused ultrasound and
  diluted calcium hydroxylapatite. Gabriela Casabona, MD – Clínica Vida;
  São Paulo, Brazil. [#7575]*

Xeomin^®

• Safety of incobotulinumtoxinA in the treatment of facial lines:
  results from a pooled analysis of randomized, prospective, controlled
  clinical studies. William P. Coleman, III, MD – Coleman Cosmetic
  Dermatologic Surgery Center; Metairie, Louisiana. [#7580]
• Efficacy of incobotulinumtoxinA for the treatment of glabellar frown
  lines in male subjects: post-hoc analyses from randomized,
  double-blind pivotal studies. Derek H. Jones, MD – Skin and Laser
  Physicians of Beverly Hills; Beverly Hills, California. [#7585]
• Safety and efficacy of escalating doses of incobotulinumtoxinA for
  extended treatment of glabellar frown lines: a randomized,
  double-blind study. Corey Maas, MD – The Maas Clinic; San Francisco,
  California. [#7651]*

Ultherapy^®

• Safety and efficacy of microfocused ultrasound with visualization for
  the correction of moderate to severe atrophic acne scars. Corey Maas,
  MD – The Maas Clinic; San Francisco, California. [#7590]

Cellfina^®

• Modified technique for tissue stabilized-guided subcision for the
  treatment of mild-to-moderate cellulite of the buttocks and thighs.
  Omar Ibrahim, MD – SkinCare Physicians; Chestnut Hill, Massachusetts.
  [#6070]*

Radiesse^®

• Dissolving calcium hydroxylapatite filler using sodium thiosulfate: a
  proof-of-concept clinical study. Deanne Mraz Robinson, MD –
  Connecticut Dermatology Group; Norwalk, Connecticut. [#7598]*
• Sodium thiosulfate injection dissolves calcium hydroxylapatite
  particles: an animal study. Peter Kreymerman, MD – Merz North America,
  Inc.; Raleigh. [#7556]
• Pilot study examining the safety and efficacy of calcium
  hydroxylapatite filler with integral lidocaine to correct jawline
  volume loss: an update at 12 months. Margit Juhász, MD – Marmur
  Medical; New York. [#7134]*
• Improvement of chin profile using calcium hydroxylapatite with
  integral lidocaine. John Fezza, MD – Center For Sight; Sarasota,
  Florida. [#7489]*

DeScribe^®
PFD Patch

• Perfluorodecalin-infused patch in picosecond and Q-switched
  laser-assisted tattoo removal: assessments of optical transparency,
  chemical stability and safety. Jeremy Brauer, MD – The Ronald O.
  Perelman Department of Dermatology, New York University School of
  Medicine, New York. [#7605]

*Investigator-Initiated Trial supported by Merz.

XEOMIN^® IMPORTANT CONSUMER SAFETY INFORMATION
Read
the Medication Guide before you start receiving XEOMIN^® (Zeo-min)
and each time XEOMIN^® is given to you as there may be new
information. The risk information provided here is not comprehensive. To
learn more:

• Talk to your health care provider or pharmacist
• Visit www.xeominaesthetic.com
  to obtain the FDA-approved product labeling
• Call 1-866-862-1211

Uses
XEOMIN^® is a prescription medicine that is
injected into muscles and used to improve the look of moderate to severe
frown lines between the eyebrows (glabellar lines) in adults for a short
period of time (temporary).

Warnings

XEOMIN^® may cause serious side effects that
can be life threatening. Call your doctor or get medical help right away
if you have any of these problems anytime (hours to week) after
treatment with XEOMIN^®:

• Problems with swallowing, speaking, or breathing. These problems
  can happen hours to weeks after an injection of XEOMIN^® if
  the muscles that you use to breathe and swallow become weak after the
  injection. Death can happen as a complication if you have severe
  problems with swallowing or breathing after treatment with XEOMIN^®.
• People with certain breathing problems may need to use muscles in
  their neck to help them breathe and may be at greater risk for serious
  breathing problems with XEOMIN^®.
• Swallowing problems may last for several months. People who cannot
  swallow well may need a feeding tube to receive food and water. If
  swallowing problems are severe, food or liquids may go into your
  lungs. People who already have swallowing or breathing problems before
  receiving XEOMIN^® have the highest risk of getting these
  problems.
• Spread of toxin effects. In some cases, the effect of botulinum
  toxin may affect areas of the body away from the injection site and
  cause symptoms of a serious condition called botulism. The symptoms of
  botulism include: loss of strength and muscle weakness all over the
  body, double vision, blurred vision and drooping eyelids, hoarseness
  or change or loss of voice, trouble saying words clearly, loss of
  bladder control, trouble breathing, trouble swallowing.

These problems could make it unsafe for you to drive a car or do other
dangerous activities.

Do not use XEOMIN^® if you are allergic to XEOMIN^® or
any of the ingredients in XEOMIN^® (see the end of this Guide
for a list of ingredients in XEOMIN^®, had an allergic
reaction to any other botulinum toxin products such as
rimabotulinumtoxinB (MYOBLOC^®), onabotulinumtoxinA (BOTOX^®,
BOTOX^® COSMETIC), or abobotulinumtoxinA (DISPORT^®)
or have a skin infection at the planned injection site.

Ask a doctor before use if you

• have a disease that affects your muscles and nerves (such as
  amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease],
  myasthenia gravis or Lambert-Eaton syndrome)
• have had any side effect from any other botulinum toxin in the past
• have a breathing problem such as asthma or emphysema
• have a history of swallowing problems or inhaling food or fluid into
  your lungs (aspiration)
• have bleeding problems
• have drooping eyelids
• have plans to have surgery
• have had surgery on your face
• are pregnant or plan to become pregnant. It is not known if XEOMIN^® can
  harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if XEOMIN^® passes
  into breast milk.
  XEOMIN^® is not recommended for use
  in children younger than 18 years of age.

Tell your doctor about all of your medical conditions and all of
the medicines you take, including prescription and over-the-counter
medicines, vitamins and herbal supplements. Using XEOMIN^® with
certain other medicines may cause serious side effects. Do not
start any new medicines until you have told your doctor that you have
received XEOMIN^® in the past.

Especially tell your doctor if you

• have received any other botulinum toxin product in the last four months
• have received injections of botulinum toxin such as
  rimabotulinumtoxinB (MYOBLOC^®), onabotulinumtoxinA (BOTOX^®,
  BOTOX^® COSMETIC) and abobotulinumtoxinA (DISPORT^®)
  in the past. Be sure your doctor knows exactly which product you
  received. The dose of XEOMIN^® may be different from other
  botulinum toxin products that you have received.
• have recently received an antibiotic by injection
• take muscle relaxants
• take an allergy or cold medicine
• take a sleep medicine
• take a blood thinner medicine

Ask your doctor if you are not sure if your medicine is one that is
listed above.

Possible Side Effects
XEOMIN^® can
cause serious side effects that can be life threatening. See “Warnings.”

Headache was the most common side effect of XEOMIN^® for
treatment of glabellar lines. Other possible side effects include:

• dry mouth
• discomfort or pain at the injection site
• tiredness
• neck pain
• muscle weakness
• eye problems, including: double vision, blurred vision, drooping
  eyelids, swelling of your eyelids, and dry eyes. Reduced blinking can
  also occur. Tell your doctor or get medical help right away if you
  have eye pain or irritation following treatment.

XEOMIN^® may cause other serious side effects
including allergic reactions. Symptoms of an allergic reaction to
XEOMIN^® may include: itching, rash, redness, swelling,
wheezing, asthma symptoms, or dizziness or feeling faint. Tell your
doctor or get medical help right away if you get wheezing or asthma
symptoms, or if you get dizzy or faint.

These are not all the possible side effects of XEOMIN^®. Call
your doctor for medical advice about side effects. You may report side
effects to FDA at 1-800-FDA-1088.

Directions

• XEOMIN^® is a shot (injection) that your doctor will give
  you.
• XEOMIN^® is injected into your affected muscles.
• Your doctor may change your dose of XEOMIN^® until you and
  your doctor find the best dose for you.

General information about the safe and effective use of XEOMIN^®
Medicines
are sometimes prescribed for purposes other than those listed in a
Medication Guide. Do not use XEOMIN^® for a condition for
which it was not prescribed. Do not give XEOMIN^® to other
people, even if they have the same symptoms that you have. It may harm
them. You can ask your pharmacist or doctor for information about XEOMIN^® that
is written for health professionals.

Active Ingredient: incobotulinumtoxinA
Inactive
Ingredients: human albumin and sucrose

Please see accompanying XEOMIN^® full Prescribing
Information and Medication
Guide.

Copyright © 2016 Merz North America, Inc. All rights reserved.

MERZ, the MERZ logo and XEOMIN are registered trademarks of Merz Pharma
GmbH & Co. KgaA.

Radiesse is a registered trademark of Merz North America, Inc. Ultherapy
and Cellfina are registered trademarks of Ulthera, Inc. DeScribe is a
registered trademark of ONLight Sciences, Inc. Botox, Dysport and
Myobloc are registered trademarks of their respective owners.

About Merz North America, Inc.
Merz North America, Inc. is a
specialty healthcare company dedicated to the development and marketing
of innovative quality products for physicians and patients across the
United States and Canada. Merz products are distributed through two
divisions, Aesthetics and Neurosciences, and are developed with the goal
of improving patients’ health and quality of life by delivering
therapies that bring about real progress. Merz North America is a
privately-held company based in Raleigh, North Carolina. To learn more
about Merz North America, Inc., please visit www.merzusa.com.